Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection
Alzheimer's disease is a progressive neurodegenerative disease that typically manifests
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …
Brain health: the importance of recognizing cognitive impairment: an IAGG consensus conference
Cognitive impairment creates significant challenges for patients, their families and friends,
and clinicians who provide their health care. Early recognition allows for diagnosis and …
and clinicians who provide their health care. Early recognition allows for diagnosis and …
[HTML][HTML] Development of a novel dementia risk prediction model in the general population: A large, longitudinal, population-based machine-learning study
Background The existing dementia risk models are limited to known risk factors and
traditional statistical methods. We aimed to employ machine learning (ML) to develop a …
traditional statistical methods. We aimed to employ machine learning (ML) to develop a …
Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment
G Lombardi, G Crescioli, E Cavedo… - Cochrane Database …, 2020 - cochranelibrary.com
Background Mild cognitive impairment (MCI) due to Alzheimer's disease is the symptomatic
predementia phase of Alzheimer's disease dementia, characterised by cognitive and …
predementia phase of Alzheimer's disease dementia, characterised by cognitive and …
[HTML][HTML] Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid-and 18F-FDG-PET imaging
J Ottoy, E Niemantsverdriet, J Verhaeghe… - NeuroImage: Clinical, 2019 - Elsevier
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …
Olfactory function in mild cognitive impairment and Alzheimer's disease: A meta‐analysis
HJ Jung, IS Shin, JE Lee - The Laryngoscope, 2019 - Wiley Online Library
Objective Olfactory function is altered in mild cognitive impairment (MCI) and Alzheimer's
disease (AD); therefore, it may serve as a useful tool for the early detection of MCI before its …
disease (AD); therefore, it may serve as a useful tool for the early detection of MCI before its …
[HTML][HTML] Random forest prediction of Alzheimer's disease using pairwise selection from time series data
PJ Moore, TJ Lyons, J Gallacher… - PloS one, 2019 - journals.plos.org
Time-dependent data collected in studies of Alzheimer's disease usually has missing and
irregularly sampled data points. For this reason time series methods which assume regular …
irregularly sampled data points. For this reason time series methods which assume regular …
EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects
We studied whether electroencephalography (EEG)-derived measures of brain oscillatory
activity are related to clinical progression in nondemented, amyloid positive subjects. We …
activity are related to clinical progression in nondemented, amyloid positive subjects. We …
Subjective cognitive decline: preclinical manifestation of Alzheimer's disease
Y Lin, PY Shan, WJ Jiang, C Sheng, L Ma - Neurological Sciences, 2019 - Springer
Subjective cognitive decline (SCD), characterized by a very early and subtle cognitive
decline prior to the appearance of objective cognitive impairment, is considered to be the …
decline prior to the appearance of objective cognitive impairment, is considered to be the …